AlveoGene is working in partnership with the Oxford-Harrington Rare Disease Centre this week at the 2024 Oxford Harrington Rare Disease Symposium, which is taking place at Trinity College Oxford from 24-26 September.
David Hipkiss, Executive Chair be presenting AlveoGene‘s outstanding year of progress as we continue on our mission to transform rare respiratory disease outcomes using inhaled gene therapy.
AlveoGene’s InGenuiTy® platform uniquely combines efficacy, durability and convenience with potential lifelong protection from a single dose.
The Company will provide updates on our pipeline progress and latest developments in neonatal surfactant protein deficiencies (Lethal SP-B and ABCA3), Alpha-1 anti-trypsin deficency (AATD), and IPF.
